Experimental models have demonstrated the importance of EGFR activation in KRAS-mutant pancreatic cancer [86,87], indicating that RAS/MAPK pathway activation is not sufficient to drive pancreatic tumorigenesis. This evidence concerns the gene KRAS and pancreatic neoplasm.